Skip to content

The impact of the third dose of inactivated vaccine against Novel Coronavirus on human immune response

The impact of the third dose of inactivated vaccine against Novel Coronavirus on human immune response

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048665
Enrollment
Unknown
Registered
2021-07-12
Start date
2021-07-12
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Morning group:Vaccinated the third dose of COVID-19 inactivated vaccine in the morning
Afternoon group:Vaccinated the third dose of COVID-19 inactivated vaccine in the afternoon

Sponsors

the First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 59 years; 2.Participants who had finished two dose of inactivated vaccine against Novel Coronavirus of Beijing biological vaccine.

Exclusion criteria

Exclusion criteria: 1.Patients are allergic to any component of the vaccine, and those who have history of severe allergic reactions to the vaccine, such as acute allergic reactions, urticaria, skin eczema, dyspnea, angioedema or abdominal pain; 2.Patients with fever, acute disease, severe chronic disease or acute onset of chronic disease; 3.Pregnant women, lactating women, or having a pregnancy plan within 3 months; 4.Patients with a history or family history of convulsions, epilepsy, encephalopathy or mental illness; Patients with uncontrolled epilepsy and other progressive neurological diseases; Patients with a history of Guillain-Barré syndrome; 5.Has been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other autoimmune disease; 6.Known or suspected suffering from serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, malignant tumors; 7.A history of COVID-19 infection; 8.Patients who take medicine affecting the immune function, such as immunosuppressant agents or immunopotentiators or glucocorticoids (>=10mg prednisone or other equivalent glucocorticoids) within one month before enrollment; 9.Patients are considered unsuitable for vaccination by clinicians.

Design outcomes

Primary

MeasureTime frame
Novel Coronavirus receptor binding domain specific antibody levels;

Secondary

MeasureTime frame
Immunocell phenotype;Adverse reaction;

Countries

China

Contacts

Public ContactPeng Sui

the First Affiliated Hospital, Sun Yat-sen University

pengsui@vip.163.com+86 13660652577

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026